New Breast Cancer Prevention Study

Women at increased risk for breast cancer may be eligible to participate in a new breast cancer prevention study through the Carole and Ray Neag Comprehensive Cancer Center.

The ExCel research study is an international effort aimed at discovering whether a certain treatment can help prevent breast cancer. The medication is from a class of drugs, aromatase inhibitors, that suppresses estrogen production. Aromatase inhibitors are already approved to treat advanced breast cancer.

Participants will receive either study drug or placebo and will be followed for five years. To be eligible, women must be postmenopausal, over 35 years old, and have an increased risk of developing breast cancer.

The study is one of many ways experts at the Neag Comprehensive Cancer Center help women understand – and potentially lower – their risk of breast cancer.